William Osler

Prominent Clinical Rheumatologist, Dr. John Beary, Joins NDA Partners as Expert Consultant

Retrieved on: 
Thursday, April 6, 2023
William Osler, Gout, University, Health Affairs, Senior, Johns Hopkins Hospital, Osteoporosis, Consultant, Pharmacy, ICH, Rheumatology, Research, Georgetown University, Government, Harvard Medical School, Medicine, DOD, National Institute of Pharmaceutical Education and Research, Hajipur, PERI, American Board of Commissioners for Foreign Missions, Committee, International Conference on Nuclear Disarmament, Oslo, 2008, Division, Hospital for Special Surgery, American Board of Internal Medicine, Internal medicine, Lahey Hospital & Medical Center, Knowledge, Human musculoskeletal system, Pharmaceutical Research and Manufacturers of America, Immunology, Research institute, Hospital, Notre Dame, Conference, Department of Defence, Rheumatoid arthritis, Pharmaceutical industry

WASHINGTON, April 6, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. John Beary, an experienced clinical rheumatologist with more than 30 years of experience in clinical drug development and regulation, has joined the firm as an Expert Consultant. Dr. Beary's expertise focuses on musculoskeletal/immunology/ rheumatology projects and throughout his career, he has served in academic, industry, and government roles including more than 40 years in clinical rheumatology and academic medicine.

Key Points: 
  • NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. John Beary, an experienced clinical rheumatologist with more than 30 years of experience in clinical drug development and regulation, has joined the firm as an Expert Consultant.
  • Throughout his career, Dr. Beary has served in academic, industry, and government roles including more than 40 years in clinical rheumatology and academic medicine.
  • WASHINGTON, April 6, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. John Beary , an experienced clinical rheumatologist with more than 30 years of experience in clinical drug development and regulation, has joined the firm as an Expert Consultant.
  • Dr. Beary was formerly Professor of Clinical Medicine, Division of Immunology and Rheumatology with the University of Cincinnati where his research focused on rheumatoid arthritis, osteoporosis, and gout.

CVS Health Appoints Dr. Jeffrey Balser to Board of Directors

Retrieved on: 
Tuesday, September 13, 2022
Tulane University, Health, National academy, Department, Director, Vanderbilt University School of Medicine, NYSE, Nursing, Vanderbilt University Medical Center, Hopkins, Company, National Academy of Medicine, Dean, CVS Health, Independent, Social media, VUMC, Academic health science centre, Physician, Johns Hopkins, CEO, Pharmacist, ICU, The Advisory Board Company, Leadership, Practitioner, Board, Heart, Research, Hospital, School, NIH, Conditional sentence, William Osler, Management, MD, Anesthesiology

WOONSOCKET, R.I., Sept. 13, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) has appointed Jeffrey R. Balser, M.D., Ph.D., to serve on the Board of Directors (the "Board") of CVS Health, effective immediately.

Key Points: 
  • WOONSOCKET, R.I., Sept. 13, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) has appointed Jeffrey R. Balser, M.D., Ph.D., to serve on the Board of Directors (the "Board") of CVS Health, effective immediately.
  • "Dr. Balser's extensive experience in a wide range of roles across health care organizations will be an invaluable asset for the Board," said CVS Health President and CEO Karen S. Lynch.
  • "On behalf of the Board, I want to welcome Dr. Balser to CVS Health," said Roger N. Farah, Independent Chair of the Board.
  • CVS Health is the leading health solutions company, delivering care like no one else can.

Longo’s Family Charitable Foundation commits $150,000 to area hospitals hardest hit by COVID-19

Retrieved on: 
Wednesday, August 4, 2021
Longos, Trillium Health Partners, William Osler, Osler, Foundation, Charity, Ethics, Articles, Medicine

MISSISSAUGA, Ontario, Aug. 04, 2021 (GLOBE NEWSWIRE) -- In response to COVID-19 and in support of area hospitals hardest hit by the pandemic, the Longos Family Charitable Foundation has generously donated $150,000 toward Mackenzie Health, Trillium Health Partners (THP) and William Osler Health System (Osler).

Key Points: 
  • MISSISSAUGA, Ontario, Aug. 04, 2021 (GLOBE NEWSWIRE) -- In response to COVID-19 and in support of area hospitals hardest hit by the pandemic, the Longos Family Charitable Foundation has generously donated $150,000 toward Mackenzie Health, Trillium Health Partners (THP) and William Osler Health System (Osler).
  • A leader in philanthropy, the Longo family is committed to supporting health care in the communities where they operate.
  • To inspire community contributions, the Longos Family Charitable Foundation will match all offers received from donors up to $150,000.
  • We are incredibly proud to be supporting these three hospitals, says Rosanne Longo, Longos Spokesperson and Chair, Longos Family Charitable Foundation.

SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus

Retrieved on: 
Monday, August 2, 2021
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medical specialties, Autoimmune diseases, Clinical medicine, Medicine, Cutaneous lupus erythematosus, Connective tissue diseases, Lupus, William Osler, Syndromes, Anifrolumab, Sjögren syndrome, Rheumatology

AstraZenecas SAPHNELO (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Key Points: 
  • AstraZenecas SAPHNELO (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
  • SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
  • Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.
  • The Companys growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases.

Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Cutaneous lupus erythematosus, Connective tissue diseases, Lupus, William Osler, Autoimmune disease, Sjögren syndrome, Lupus erythematosus

It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.

Key Points: 
  • It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.
  • With the approval of Saphnelo, we now have one more drug that allows us to translate valuable research knowledge into clinical practice with multiple benefits for our patients with lupus."
  • Saphnelo showed benefits on overall lupus disease activity, skin lupus and joints and the ability to taper down steroid doses.
  • The Lupus Foundation of America's research during the 1980s contributed to the development of Saphnelo through its support of research on interferons.

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Cutaneous lupus erythematosus, Medicine, Clinical medicine, Autoimmune diseases, Lupus, William Osler, Draft:Lupus UK, Lupus Foundation of America

Given by intravenous infusion, anifrolumab-fnia works by blocking immune system molecules called type I interferons that are one of the main factors that leads to tissue damage and disease symptoms. Type I interferons are a family of 17 similar molecules that help protect us from infections.i Research has shown that the vast majority -- 60-80 percent of adultsii -- have high levels of type I interferons.

Key Points: 
  • The approval represents the first new treatment for generalized SLE in more than a decade and is the result of significant seminal research funded originally by the Lupus Research Alliance.
  • One of the trailblazers in interferon research is former chair of the Lupus Research Alliance Scientific Advisory Board Dr. Mary Crow.
  • Over the past two decades, the Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Cutaneous lupus erythematosus, Medicine, Clinical medicine, Autoimmune diseases, Lupus, William Osler, Draft:Lupus UK, Lupus Foundation of America

Given by intravenous infusion, anifrolumab-fnia works by blocking immune system molecules called type I interferons that are one of the main factors that leads to tissue damage and disease symptoms. Type I interferons are a family of 17 similar molecules that help protect us from infections.i Research has shown that the vast majority -- 60-80 percent of adultsii -- have high levels of type I interferons.

Key Points: 
  • The approval represents the first new treatment for generalized SLE in more than a decade and is the result of significant seminal research funded originally by the Lupus Research Alliance.
  • One of the trailblazers in interferon research is former chair of the Lupus Research Alliance Scientific Advisory Board Dr. Mary Crow.
  • Over the past two decades, the Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Lupus Foundation of America Provides Six Grants to Young Scientists Supporting Important Lupus Research

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Medicine, Clinical medicine, Cutaneous lupus erythematosus, Lupus, William Osler, Lupus Canada

The fellowship program provides grant and mentorship support for young scientists and plays an important role in establishing the next generation of lupus researchers and the future of the lupus research field.

Key Points: 
  • The fellowship program provides grant and mentorship support for young scientists and plays an important role in establishing the next generation of lupus researchers and the future of the lupus research field.
  • Each 2021 Finzi awardee is mentored throughout their research project by an experienced lupus investigator, a critical component ensuring that the young scientists receive support and guidance as they establish themselves in lupus research.
  • The Gina M. Finzi Memorial Student Summer Fellowship Program has supported the work of nearly 200 young scientists in North America.
  • Past recipients from the program have gone on to lead innovative and groundbreaking lupus research and have become distinguished lupus scientists in the field.

AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions

Retrieved on: 
Tuesday, July 13, 2021
Autoimmune diseases, Medical specialties, Clinical medicine, Cutaneous lupus erythematosus, Medicine, Lupus, William Osler, Connective tissue diseases, Anti-SSA/Ro autoantibodies

This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.

Key Points: 
  • This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.
  • Assessment of the confidence in the diagnosis of SLE and initiation of hydroxychloroquine (HCQ) showed that the AVISE Lupus test impacted physician behavior.
  • In particular, physician certainty in an SLE diagnosis increased with increasing AVISE Lupus scores.
  • Similarly, certainty in an SLE diagnosis decreased when an AVISE Lupus score was negative, indicating that the test helped in both ruling-in and in ruling-out the disease.

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Retrieved on: 
Monday, July 12, 2021
Medical specialties, Clinical medicine, Medicine, Kidney diseases, Cutaneous lupus erythematosus, Lupus, William Osler, Graft-versus-host disease, Nephritis

The meeting confirmed a path to advance itolizumab into a single Phase 3 pivotal study to support the Biologics License Application (BLA) filing for itolizumab in first-line treatment of aGVHD patients.

Key Points: 
  • The meeting confirmed a path to advance itolizumab into a single Phase 3 pivotal study to support the Biologics License Application (BLA) filing for itolizumab in first-line treatment of aGVHD patients.
  • The company plans to initiate the Phase 3 study in Q4 2021.
  • Equillium is finalizing details of the Phase 3 protocol based on feedback and guidance from the FDA.
  • Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including a planned pivotal study in acute graft-versus-host-disease (aGVHD), a Phase 1b study in lupus/lupus nephritis and a Phase 1b study in uncontrolled asthma.